AbstractObjectives. We sought to determine the electrophysiologic mechanisms explaining the efficacy of combination therapy with dl-sotalol and a type Ia drug in the treatment of ventricular tachycardia (VT).Background. Combination antiarrhythmic drug therapy with low dose dl-sotalol plus a type Ia antiarrhythmic agent has been shown to prevent spontaneous and induced VT. The mechanisms underlying the efficacy of this drug combination have not been fully elucidated.Methods. We studied 32 patients with spontaneous sustained VT by using programmed electrical stimulation in the drug-free condition and after treatment with dl-sotalol (average dose [mean ± SE] 151 ± 8 mg/day) and a class Ia agent (quinidine, 1,337 ± 59 mg/day, or procainamide, 2...
OBJECTIVES:This study was undertaken to assess the effects of sotalol on the transthoracic cardiover...
Studies in animals have shown that drug-induced action potential prolongation with class III antiarr...
AbstractSixty-five patients with symptomatic, drug-refractory, sustained ventricular tachycardia or ...
ABSTRACT Eighteen patients with sustained ventricular tachycardia underwent electrophysiologic studi...
Although discovered more than two decades ago, the clinical applications of sotalol are still a matt...
Aims: In selecting effective antiarrhythmic agents for reentrant ventricular tachycardia (VT), there...
o evaluate the clinical efficacy of d-sotalol, 84 patients with a history of sustained ventricular t...
Sotalol is a unique beta-adrenergic blocking agent with additional actions characteristic of Vaughn-...
AbstractObjectives. This study assessed the efficacy of the combination of sotalol and either quinid...
AbstractObjectivesWe sought to determine the electrophysiologic actions of sotalol in the remodeled ...
AbstractObjectives. This study examines the effects of sotalol on the signal-averaged electrocardiog...
AbstractObjectives. This study evaluates the clinical efficacy of d,l-sotalol in patients with susta...
Sotalol is a beta-adrenergic blocking agent that prolongs the duration of the cardiac action potenti...
OBJECTIVES: We sought to determine the electrophysiologic actions of sotalol in the remodeled atrium...
AbstractOBJECTIVESWe sought to study the rate related effects of sotalol on myocardial contractility...
OBJECTIVES:This study was undertaken to assess the effects of sotalol on the transthoracic cardiover...
Studies in animals have shown that drug-induced action potential prolongation with class III antiarr...
AbstractSixty-five patients with symptomatic, drug-refractory, sustained ventricular tachycardia or ...
ABSTRACT Eighteen patients with sustained ventricular tachycardia underwent electrophysiologic studi...
Although discovered more than two decades ago, the clinical applications of sotalol are still a matt...
Aims: In selecting effective antiarrhythmic agents for reentrant ventricular tachycardia (VT), there...
o evaluate the clinical efficacy of d-sotalol, 84 patients with a history of sustained ventricular t...
Sotalol is a unique beta-adrenergic blocking agent with additional actions characteristic of Vaughn-...
AbstractObjectives. This study assessed the efficacy of the combination of sotalol and either quinid...
AbstractObjectivesWe sought to determine the electrophysiologic actions of sotalol in the remodeled ...
AbstractObjectives. This study examines the effects of sotalol on the signal-averaged electrocardiog...
AbstractObjectives. This study evaluates the clinical efficacy of d,l-sotalol in patients with susta...
Sotalol is a beta-adrenergic blocking agent that prolongs the duration of the cardiac action potenti...
OBJECTIVES: We sought to determine the electrophysiologic actions of sotalol in the remodeled atrium...
AbstractOBJECTIVESWe sought to study the rate related effects of sotalol on myocardial contractility...
OBJECTIVES:This study was undertaken to assess the effects of sotalol on the transthoracic cardiover...
Studies in animals have shown that drug-induced action potential prolongation with class III antiarr...
AbstractSixty-five patients with symptomatic, drug-refractory, sustained ventricular tachycardia or ...